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Treatment of osteoarthritis (OA) with anti-
remodeling agents has had a mixed record of 
results. It is likely that remodeling suppression 
is only effective when used in the early phases 
of OA, before significant progression.  Animal 
and human studies largely bear this out. Treat-
ment of young mice with a RANKL inhibitor 
suppresses bone resorption and prevents OA 
progression. Likewise, bisphosphonate treat-
ments in rodents and rabbits with induced 
injury or inflammatory arthritis, reduced car-
tilage degeneration when administered pre-
emptively, but later administration did not. 
The increased prevalence of OA in women af-
ter the menopause, and presence of estrogen 
receptors in joint tissues, suggests that treat-
ment with estrogens or Selective Estrogen Re-
ceptor Modulators may be effective. However, 
in clinical trials of knee and hip, results show 
decreased or increased risk for OA, or no ef-
fect. Raloxifene had positive effects in animal 
models, but no effect in human studies. More 
recent potential treatments such as strontium 
ranelate or cathepsin-K inhibitors may be ef-
fective, but may work directly on the cartilage 
rather than through their well-known effects 
on bone. The conclusion from these studies is 
that anti-remodeling agents must be adminis-
tered pre-emptively or in the very early stages 
of disease to be effective. This means that 
better imaging techniques or identification of 
early structural changes in bone that occur 
before progressive cartilage destruction must 
be developed. 
Key Words: Osteoarthritis, bisphosphonate, 
estrogen, cartilage, bone. 
Introduction
Treatment of osteoarthritis (OA) with agents 
that suppress overall bone remodeling that 
were originally developed for the treatment 
of postmenopausal osteoporosis has had a 
mixed record of results. When bone anti-re-
modeling (or anti-catabolic) treatments have 
been used to reduce the effects of human OA, 
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the trials have almost universally failed.1,2 The 
idea of anti-catabolic treatment is that sup-
pression of early phase subchondral bone re-
modeling can prevent or ameliorate vascular 
invasion to the cartilage, and subsequent ef-
fects of cartilage fibrillation and loss. To un-
derstand why the results of animal studies and 
human clinical trials have mixed results, it is 
important to understand the phases of OA de-
velopment.3
Historically, OA was thought to be asso-
ciated with subchondral sclerosis which was 
considered by some to be causative.4-6The 
theory was that dense subchondral bone, 
being stiffer and less able to absorb joint 
stresses, caused increased stress in the deep 
layers of the cartilage,7,8 initiating the progres-
sive process of cartilage fibrillation and loss.
There was some experimental evidence that 
this was the case.9,10 More recent observa-
tions have demonstrated that in early OA, 
conversely, there is subchondral plate thin-
ning, and cancellous bone loss caused by an 
increase in remodeling rate (Figure 1).11,12 This 
is followed by reduced remodeling with an im-
balance between resorption and formation in 
favor of formation.13 This later phase reduction 
in remodeling causes the subchondral plate 
to thicken14 giving the radiologic appearance 
of sclerosis, even though the mineralization 
of the tissue itself may be reduced,15 and the 
subchondral cancellous bone beneath it may 
remain osteopenic.16
Because subchondral sclerosis is an end-
stage product of the disease, it is likely that anti-
catabolic treatments can only be effective when 
used in the early phases of OA development, 
before significant progression has occurred. 
Certainly, giving an anti-catabolic treatment 
when bone density is already greatly increased 
would make little sense. Animal experiments 
show that inducing subchondral sclerosis with-
out permitting the prior stage of increased bone 
remodeling can prevent progressive cartilage 
fibrillation and loss,17-20 demonstrating that the 
early phase increased remodeling, together with 
the increased vascularity that accompanies it, is 
a necessary pathogenetic condition for progres-
sive OA to develop.
Even so, clinical studies using anti-cata-
bolic agents provide conflicting and inconsis-
tent results2,21 and research into both the safe-
ty and the efficacy of these agents continues. 
The confusion over the potential use of these 
agents is reflected by the recent position pa-
per from the American College of Rheumatol-
ogy for use of non-pharmacologic and phar-
macologic therapies in OA of the hand, hip 
and knee,22 which did not recommend any 
anti-catabolic therapies for the treatment or 
prevention of OA.
Clinical Studies
Bisphosphonate (BP) treatments for OA
One of the earliest prospective trials using 
the BP risedronate (RIS) enrolled 284 sub-
jects with mild to moderate OA into a double-
blind placebo controlled study.23 Subjects 
were treated with 5 or 15 mg/day. Although 
the study found more subjects with radio-
graphic evidence of joint space narrowing
in the untreated group, the numbers were 
small (placebo n=7; 5 mg RIS n=4; 15 mg RIS 
n=1) and not statistically significant.
A large multi-center study was initiated RIS 
at doses of 5, 15 or 35 mg/week in Europe 
and 50 mg/week in the U.S. Nearly 2,500 pa-
tients with established medial compartment 
knee OA were identified and treated for two 
years.1 Progression of OA was identified by an 
increase of joint space narrowing (JSN) in the 
knee joint, assessed by radiography, greater 
than 0.6 mm over the treatment period. Al-
though the treatment appeared to reduce pain 
(assessed by WOMAC score) and reduced 
CTX-II, a measure of cartilage catabolism, in 
both the U.S. and Europe, it had no effect on 
progression of OA at any dose on either conti-
nent (Figure 2). For all treatment groups, about 
10-13% of the subject population continued 
to progress. 
Earlier, Carbone et al.24 had used MRI to 
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compare knee and patello-femoral pain and 
bone in women either with or without exist-
ing OA who were using anti-catabolic agents 
(estrogen, raloxifene or RIS) or were treat-
ment naïve. They were unable to identify any 
relationship between anti-resorptive use and 
radiographic evidence that progression of 
knee OA was slowed by any of the specific 
anti-remodeling agents for knee OA, or when 
the treatment groups were pooled. However, 









Cancellous bone remains 
osteopenic
Figure 1. The initiation of osteoarthritis (OA) and the progression of OA are associated with distinctly differ-
ent processes in the subchondral bone. In early phases of OA, there is an increased rate of bone turnover, 
leading to a loss of bone volume and thinning of the subchondral plate. In established OA, this process is 
reversed, with reduced bone remodeling and an imbalance in favor of bone formation. This leads to the 
subchondral sclerosis that is characteristic of established OA. R-F: resorption-formation (Reproduced with 
permission from Ref 3).
Both may be required for disease progression 
Actualizaciones en Osteología,  VOL. 12 - Nº 3 - 2016200
David B. Burr: Anti-resorptive agents and osteoarthritis
they did find a reduction in pain and less mar-
row edema – what we would now call bone 
marrow lesions (BMLs) – in those who used 
either estrogen or alendronate (ALN), but a 
more pronounced reduction in those using 
ALN, with an 89% reduction in odds ratio after 
adjusting for co-variates. This is probably not 
surprising given ALN´s potent anti-remodeling 
effects.  However, they were not able to detect 
any significant change in cartilage lesions, and 
did not examine changes in joint space width, 
and so were unable to correlate the prevention 
of bone changes associated with OA with car-
tilage loss itself. The duration of the use of the 
medications was not specified, and likely var-
ied widely among the 214 women who were 
using anti-remodeling therapies.
A more recent study compared patients 
with early stage radiographic knee OA who 
were classified as either BP users (ALN or 
RIS) or BP-naïve.25  This study showed signifi-
cantly fewer patients with OA progression in 
those taking BPs after three years of observa-
tion (p=0.041), although this significance was 
lost in year four (p=0.057). Further, a trend to-
wards reduced joint space narrowing by year 
three was also observed (p=0.083 in year 3, 
and 0.057 in year 4) (Figure 3). This suggests 
that the duration of treatment may be impor-
tant to identifying the efficacy of BPs for OA 
progression, which makes logical sense given 
the long period required for OA to develop.
Estrogen and Selective Estrogen Receptor 
Modulators (SERMs)
The increased prevalence of OA in women 
after the menopause,26 and presence of es-
trogen receptors in joint tissues,27-29 suggests 
that treatment with estrogens or SERMs may 
be an effective treatment for OA progression 
with direct effects on both bone and carti-
lage or synovial tissues. However, in clinical 
trials of both knee and hip, results of hor-
mone replacement therapy have been mixed, 
Risedronate and OA progression: Human Studies
Figure 2. An early clinical study showed that treatment with the bisphosphonate risedronate led to a non-
significant reduction in Type II collagen (CTXII) degradation in cartilage, but had no effect on progression 
of OA even at higher doses (Data from Ref 1).
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with reports of decreased prevalence of OA 
[the Chingford study for radiologic OA of the 
knee;30,31 the SOF study with a longer duration 
of treatment for hip OA32,33]; increased risk for 
OA [for radiologic OA of the knee;34,35 and the 
Rancho Bernardo study for clinical OA of the 
hip36]; or of no effect of treatment on radio-
logic37,38 or clinical24,39,40 OA of the knee or hip. 
The inconsistent results may in part reflect a 
dose-response effect as higher doses of es-
trogens are known to have catabolic effects, 
whereas lower doses have been shown to be 
chondroprotective in some instances.41-43 In 
the Framingham study, although the odds ra-
tio for a protective effect of HRT on OA was 
not significant, there appeared to be a dura-
tion effect with use of > 5 years associated 
with a lower risk of knee OA than shorter-
term use.44 This is consistent with a separate 
study which showed that women taking HRT 
for more than 5 years had greater tibial car-
tilage volume, measured by a T1-weighted 
fat-suppressed MRI image and adjusted for 
covariates, than women who had never taken 
estrogen therapy.45 In the following two years 
of observation, average tibial cartilage volume 
decreased by 2.4% per year compared to 
3.2% annually in non-users, but the difference 
was not statistically significant.46 This may be 
due to the small cohort size, inability to ac-
curately measure cartilage volume, or disease 
that was only slowly or not progressing. 
It is probably not worthwhile to review 
these studies here in detail, given that many of 
them are older studies performed when estro-
gen-replacement therapy was more common 
before the Women’s Health Initiative identified 
side effects that reduced patients’ and physi-
cians’ confidence about its safety. However, 
an excellent review of this literature can be 
found in de Klerk et al.,47 who concludes that 
the preponderance of evidence suggests no 
effect of “exogenous hormone use” for the 
treatment of hand, hip or knee OA.
SERMS, on the other hand, appear to 
prevent cartilage degradation, at least when 
measured against changes in biochemical 
markers such as CTX-II. Both Levormeloxi-
Figure 3. Patients with early stage OA who were had been BP showed no significant change in joint space 
width (JSW) on average after a 3 year observation period. However, there was some evidence that BP 
slowed progression of OA. This difference reached statistical significance in year 3, but significance was 
lost in year 4, probably due to the large variation in the patient population. It is worth noting, however, that 
OA tended to progress in only about 10% of BP users, compared with nearly 80% of those not taking BPs 
(Data from Ref 25).
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fene48 and raloxifene24 reduced CTX-II follow-
ing 12 months of treatment, although no effect 
was evident on cartilage structure by MRI.24,49 
Once treatment was stopped, CTX-II reverted 
to pre-treatment levels, suggesting that the ef-
fect was short-term. However, raloxifene had 
no effect in human studies of postmenopausal 
women.49
What does this tell us?
There are several reasons that differences 
between treatment groups may not have been 
detected in many of these studies. First, OA is 
a condition that progresses very slowly, and 
it is possible that a two year treatment period 
is insufficient. Second, the patient popula-
tions were ones in which medial compartment 
OA was already well established. An anti-re-
sorptive treatment may only be beneficial in 
controlling the initial stages of the disease at 
a time when vascular invasion from the sub-
chondral bone is active. The study by Laslett 
et al.25 is instructive in showing that longer 
treatment periods are needed to demonstrate 
an effect, and that even in this case it is nec-
essary to start with a population in which the 
disease has not progressed to a moderate 
or severe level. Third, radiographic measure-
ments are insensitive to small changes in joint 
space width; changes over a short period of 
time are unlikely to be detectable. 
It is possible, however, that BPs or estro-
gens have a direct effect on cartilage constitu-
ents. BPs have been suggested to stimulate 
both collagen synthesis and aggrecan for-
mation.50 BPs at high doses also have been 
shown to block metalloproteinases (MMP-9 
and MMP-13) which are known to cleave type 
II collagen, and BPs may act directly on car-
tilage as a chondroprotective agent.51 Unlike 
their effects in bone which tend to be sus-
tained after treatment withdrawal, effects of 
ALN on CTX-II levels return to baseline rela-
tively quickly,52 suggesting independent ef-
fects on bone and cartilage.
Likewise, IGF-1 has been associated with 
radiographic OA in the Rotterdam study,53 and 
synovial IGF-1 and -2 levels are increased 
when estrogen is given unopposed by pro-
gesterone.54 Further, estradiol has an effect on 
IL-6 production by chondrocytes,55 although it 
is not clear whether this affects the catabolic 
activity of the chondrocytes. Moreover, estro-
gens may decrease the catabolic activity of 
MMP 1,56 protecting the cartilage from degra-
dation. Their role in proteoglycan synthesis is 
less clear, with reports that proteoglycan syn-
thesis is either increased57 or decreased.58,59 
These differences are likely the result of dif-
ferent doses and treatment of different chon-
drocytic cell lines. For in vivo studies, whether 
estrogens increase or decrease proteoglycan 
synthesis is likely dependent on whether the 
treatment is effective at reducing cartilage 
loss, which in turn is partially dependent on 
when the treatment is initiated.
Still, as Goldring and Berenbaum60 point 
out in a recent review, agents that directly at-
tack enzymes that degrade cartilage are not 
completely effective, or have significant side 
effects, causing their use to be discontinued. 
They suggest that prevention of disease pro-
gression may be a more effective strategy, al-
though it is necessary to identify the disease 
process early in order to manage this.
Pre-clinical models using BPs to prevent 
OA 
BPs and RANKL inhibitors
These human trials provide no evidence that 
BPs will be effective treatment modalities, al-
though the studies were limited by duration of 
treatment and by insufficient methods of imag-
ing and quantifying progressive cartilage loss in 
vivo. Animal models in which timing and dose of 
treatments can be more easily manipulated, and 
in which histological changes can be assessed 
instead of relying on imprecise imaging tech-
niques, can shed light the importance of these 
variables in assessing the efficacy of treatment.
Hayami et al.61 showed a significant reduc-
tion in cartilage damage 10 weeks following 
Actualizaciones en Osteología,  VOL. 12 - Nº 3 - 2016 203
David B. Burr: Anti-resorptive agents and osteoarthritis
ACL transection in Sprague-Dawley rats with 
ALN administered at two different doses start-
ing immediately after injury. They were further 
able to show an association with vascular in-
vasion of calcified cartilage, which was signifi-
cantly reduced especially with the higher dose 
(240 µg/kg s.c./week). Pamidronate treatment 
reduces cartilage degeneration that occurs 
within 6 weeks following complete or partial 
medial meniscectomy in ovariectomized (OVX) 
C57BL/6 (C57) mice and in mice genetically 
modified to overexpress Runx2 that have rapid 
bone turnover,62,63 but not in C57 mice crossed 
with Balb/c mice (B6CF strain). The reduction 
in cartilage degeneration may be caused by re-
duced cleavage of the proteoglycans as mark-
ers of cartilage catabolism (ADAMTS-4 and 5) 
are also reduced.62 Although pamidronate pre-
vented cartilage destruction in the Runx2 over-
expressing mice, there was no initial difference 
in cartilage deterioration between the wild-type 
B6CF mice and the over-expressers following 
partial meniscectomy, suggesting that the rapid 
bone turnover was not an underlying factor in 
the cartilage deterioration. In this study, it could 
be that pamidronate had direct effects on carti-
lage, and that the reduced bone turnover was 
not the cause of the improvement. 
Likewise, ALN partially protects rabbits from 
cartilage deterioration following ACL transection 
(ACLT).64 More potent BPs such as zoledronate 
(ZOL) completely prevented progression of car-
tilage damage in rabbits with ACLT when started 
immediately after injury.65 This may indicate that 
there is a dose effect required for prevention. 
Other studies show similar effects with BPs fol-
lowing injury-induced OA in rabbits66 and dogs,67 
although the effect on morphometric lesions is 
inconsistent.68 Not surprisingly, in all cases the 
chondroprotective effects of BPs are accompa-
nied by reduced subchondral resorption, lead-
ing some to imply a causative association,66 
but causation cannot be clearly demonstrated 
by these studies. Nevertheless, these studies 
are compelling in suggesting that BP treatment 
started soon after injury is effective in preventing 
subsequent progressive cartilage disease.
Fewer studies have been done with other po-
tent anti-catabolic treatments such as RANKL 
inhibitors. Treatment of young mice with osteo-
protegerin (OPG), a decoy receptor for RANKL, 
potently suppresses bone resorption and has 
been shown to prevent the progression of OA in 
mice [Kadri et al., 2008]. Following medial men-
iscectomy, 10 week old C57 mice were treated 
2x/week with OPG or an interleukin receptor 
antagonist (IL-RA). Cartilage in the OPG-treated 
group was maintained with almost no degra-
dation, significantly healthier than cartilage 
in the IL-RA treated or saline-treated groups. 
ADAMTS-4 and -5 positive cells were signifi-
cantly fewer in OPG-treated mice, and of course 
there were fewer osteoclasts and greater sub-
chondral bone volume. Again, this suggests that 
an agent that suppresses early remodeling fol-
lowing joint injury can prevent subsequent pro-
gressive cartilage degradation.
First generation BPs (clodronate and YM175) 
also have been shown to be effective in rat mod-
els of inflammatory arthritis induced either by 
collagen or by adjuvant.69-71 This set the stage 
for investigating the efficacy of more potent re-
cent generation BPs such as ZOL, which has 
been shown to be effective at reducing cartilage 
loss and pain in chymopapain-induced OA in 
rabbits,72 and mono-iodoacetate (MIA)-induced 
OA in rats.19,73
These studies suggest the benefits of BPs 
as chondroprotective agents, but the timing of 
treatment initiation may be critical to the effec-
tiveness of the treatment. Yu et al.18 showed that 
both the timing of treatment and the dose used 
are significant factors in effectiveness. They in-
duced medial meniscus tears in adult Sprague-
Dawley rats and observed changes over a 12 
week experimental period. They treated the rats 
with 100 µg/kg s.c. of ZOL twice a week starting 
either immediately following the injury, or 4 or 8 
weeks after injury.This model showed progres-
sive cartilage change over the 12 week period, 
but initiating ZOL treatment either immediately 
or within 4 weeks of injury caused significantly 
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less cartilage destruction than when ZOL was 
started 8 weeks after injury. A separate experi-
ment using a low dose (10 µg/kg s.c.) or the 
higher dose (100 µg/kg s.c.) administered start-
ing immediately after injury showed both doses 
of ZOL to be effective in significantly reduc-
ing cartilage damage by the end of 4 weeks, 
but with a clear dose response. This provides 
convincing evidence that pre-emptive adminis-
tration of a potent anti-catabolic agent may be 
effective at preventing subsequent progressive 
disease. 
Early administration may be effective even 
when using less potent BPs.20 ALN was used 
to prevent OVX-induced loss of cartilage over 
an 18 week period and was administered either 
immediately after OVX, or 8 weeks after OVX. 
ALN administered immediately completely pre-
vented cartilage erosion following 10 weeks of 
treatment, but ALN initiated 8 weeks following 
OVX was not effective in reducing cartilage le-
sions with 10 weeks of treatment, even though 
it prevented subchondral bone loss. This sug-
gests that the timing of initiation of treatment is 
critical to efficacy. This study also implies that 
rescue of subchondral bone is insufficient to 
prevent the changes of OA, but the prevention 
of early bone loss (and the vascularity that ac-
companies it) is associated with prevention of 
progressive cartilage disease. Whether this is 
because the bone changes were prevented, or 
that ALN acted directly on the cartilage during 
the early phases of disease cannot be deter-
mined. In this case, MMP-9 and MMP-13 levels 
were reduced20,64 as were some other cartilage 
catabolic agents such as vascular endothelial 
growth factor, VEGF, which can have an effect 
on both vascular invasion to the deep cartilage 
layers but is also produced by chondrocytes 
superficially.64
Other studies are suggestive, but have sig-
nificant problems with experimental design. 
Pre-emptive treatment was recently shown to 
be important in treatment of MIA-induced in-
flammatory arthritis in rat knees.19 In this case, 
treatment with ALN (15 µg/kg s.c. 2x/week) 
was started pre-emptively (0-2 weeks after in-
duction), early (2-6 weeks after induction) or 
late (6-10 weeks after induction). Pre-emptive 
treatment partially prevented cartilage degen-
eration, whereas early or delayed treatment 
had no effect. The modest effect of ALN, even 
when given pre-emptively, may in part be due 
to its less potent activity than ZOL. However, 
the study was flawed because animals treated 
pre-emptively were sacrificed after 2 weeks, 
whereas those treated early or later were sac-
rificed at 6 and 12 weeks respectively. Never-
theless, this implies that pre-emptive treatment 
may be effective for inflammatory arthritides as 
well as for OA. 
All of these studies suggest that early ad-
ministration of an anti-catabolic agent reduced 
cartilage degeneration, but later administration 
did not. This indicates that timing of treatment 
with an anti-remodeling agent is critical to pre-
vent the progression of early cartilage fibrilla-
tion to frank OA.
Estrogen and SERMS
Similar to human studies, the effects of es-
trogen treatment on OA in animals is unclear. 
Only half of the 22 animal studies reviewed by 
Sniekers et al.11 showed protective effects of 
estrogen treatment in mice, rats, rabbits and 
sheep. More than 25% of the studies reviewed 
showed estrogen actually to be detrimental to 
cartilage health. Delayed administration of es-
trogen in OVX rats was less effective than im-
mediate administration,74 again suggesting that 
even in the event that estrogen has benefits for 
cartilage health, treatment of established OA 
with estrogens will be ineffective. Timing is key, 
as estrogen – or any hormonal or pharmaceuti-
cal treatment - might be able to downregulate 
the catabolic functions of chondrocytes, and 
prevent vascular in growth from bone, but can-
not restore cartilage matrix once it is damaged. 
No known agent can stimulate chondrocytes 
to functionally repair cartilage that has already 
become fibrillated. 
Studies with larger animal models, and 
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those closer taxonomically to humans may be 
better indicators of whether treatment will work 
in humans. Three years of estrogen treatment 
of cynomolgus monkeys begun immediately 
following OVX was associated with less severe 
OA than in controls, when adjusted for age and 
weight.75 Either increased proteoglycan pro-
duction by chondrocytes shown in the monkey 
study,76 or possibly reduced proteoglycan deg-
radation as shown in sheep treated with estra-
diol pellets77 may account for the chondropro-
tective effects in these studies.A subsequent 
study in nonhuman primates, however, found 
neither changes in proteoglycans or any effect 
on cartilage degradation.78
Changes in proteoglycan content may 
account for a positive mechanical outcome 
even in cases when there is no apparent ef-
fect on cartilage structure. Treatment of OVX 
sheep with estradiol implants, similar to the 
subsequent Richmond study, was associat-
ed with restoration of articular cartilage mod-
ulus (stiffness) to sham values, significantly 
greater than the modulus of untreated OVX 
sheep.79
In contrast, most studies using SERMs 
to reduce cartilage degradation have shown 
positive results. In collagen-induced arthritis 
in mice with a mutated ncf1 gene, either es-
trogen or a raloxifene analogue reduced car-
tilage deterioration,80 as did levormeloxifene 
in rats,48 and tamoxifen in meniscectomized 
rabbits.81-83 Interestingly, in the mouse model 
of collagen-induced inflammatory arthritis, the 
raloxifene analogue and estrogen both were 
demonstrated to have positive effects on es-
tablished arthritis, with fewer animals present-
ing evidence of arthritic changes and with sig-
nificantly less cartilage degradation.80 The pre-
cise mechanism for this effect is unclear, but 
various signaling pathways have been impli-
cated in the beneficial effects of SERMS. One 
suggestion is that, because both raloxifene 
and tamoxifen are known to be GPER1 ago-
nists, both affect PI3K/Akt and PKC/MAPK 
pathways.
Potential new therapies
More recent potential treatments such 
as strontium ranelate (SrRan) or cathepsin-
K inhibitors (CatK) may be more effective 
than existing anti-catabolic treatments,84,85 
but may act directly on cartilage rather than 
through their well-known effects on bone. 
Interestingly, SrRan has been shown to re-
duce gene expression for CatK in a canine 
OA model,86 and in vivo studies using CatK 
in the canine model also demonstrated some 
beneficial effect.87,88
SrRan
Several human trials using SrRan for the 
treatment of OA have shown encouraging re-
sults. An early study (TROPOS) demonstrat-
ed that SrRan decreased CTX-II regardless of 
whether the patient had OA.89 This provided 
encouragement for larger and more exten-
sive trials focused on OA. The SEKOIA trial 
was an international, multi-center randomi-
zed double-blind placebo-controlled phase 3 
trial of knee OA in patients with primary knee 
OA.85,86 MRIs were used at baseline and 1,2 
and 3 years following treatment to evaluate 
cartilage volume and bone marrow lesions 
(BMLs). Treatment with SrRan at the higher 
dose (2 g/day, which is the osteoporosis 
dose) was associated with significantly less 
cartilage loss and both doses were associ-
ated with less joint space narrowing than in 
placebo controls. BMLs were reduced fol-
lowing three years of treatment, a significant 
finding given that BMLs have been shown to 
be an early indicator of progressive OA.90
A study in the ACL transection model in 
dogs, in which cartilage could be evaluated 
histologically rather than with imaging tech-
niques, supports the conclusions that SrRan 
may reduce cartilage lesions and preserve 
the collagen network, assessed by picro-
sirius red staining. The dosages used in this 
study (25, 50 and 75 mg/kg/day) span the 
range used for human osteoporosis (2 g/day 
or about ~25-40 mg/kg/day), but the greatest 
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effects were found for the higher dosages (50 
and 75 mg/kg/day) suggesting that any bene-
ficial effect of SrRan in OA may require doses 
higher than those used for postmenopausal 
osteoporosis. This could create negative side 
effects as high doses of Sr are known to sup-
press mineralization, but it is not clear whether 
the doses used in this study are sufficiently high 
to cause this. Interestingly, however, the thick-
ness of the subchondral plate was reduced at 
all doses of SrRan compared to placebo treated 
dogs, an interesting finding for an agent that is 
used in postmenopausal osteoporosis to retain 
bone.
The mechanism for the beneficial effect 
of SrRan on cartilage is not entirely clear, 
but several possibilities exist. Early obser-
vations showed that SrRan helped to pro-
mote the aggregation of proteoglycans with 
the hyaluronic backbone for form the large 
aggrecan molecules that give cartilage its 
compressive stiffness.91There is also some 
evidence in vitro that Sr may enhance the 
effects of IGF-1.92 Recent evidence in a ca-
nine model shows that SrRan downregu-
lates metalloproteinases (MMP-1, 3 and 13), 
and ADAMTS5 in cartilage, as well as IL-
1β in synovium.86 Downregulation of IL-1β 
was also shown in vitro in chondrocytes.92 
Both in vitro and in vivo studies suggest 
that SrRan may somehow re-balance an 
imbalance between chondrocyte-mediated 
cartilage catabolic and anabolic functions. 
The observation that higher doses of SrRan 
cause less loss of cartilage volume both at 
1 and 3 years of treatment also could re-
flect a retention of water rather than, or in 
addition to, a retention of the organic and 
protein matrix.
Cathepsin-K inhibitors**
Interestingly, one of the effects of SrRan is 
a significant reduction in CatK at high doses 
(75 mg/kg/day).86 This raises the possibility that 
CatK inhibitors, which have mild anti-resorptive 
effects on bone, could be effective chondro-
protective agents (Figure 4). This could counter 
the effect in human osteoarthritic cartilage of in-
creased intracellular CatK activity93 that occurs 
primarily in the superficial regions of cartilage 
which are most likely to become fibrillated,94,95 
and in OA synovium.96 CatK is known to be able 
to cleave collagen at sites that are different from 
those cleaved by MMPs93,97 and can degrade 
aggrecan.96 Preclinical studies using transgenic 
mouse models show overexpression of CatK 
in a model that develops OA,98 and a delay99 or 
prevention88 of cartilage loss in CatK knockout 
mice subjected to joint instability. In the latter 
studies, two different knockout models were 
used (Ctsk-/- and CatK-/- respectively) and two 
different models of joint instability (partial medial 
meniscectomy with transection of both MCL 
and ACL, vs. only an ACL transection, respec-
tively), reinforcing the idea that the prevention of 
OA progression in these models was the result 
of the absence of CatK. Whether CatK expres-
sion is a cause or an effect of cartilage de-
terioration is not clear, but given its catabolic 
effects on type II collagen, its overexpression 
in association with cartilage deterioration at 
least suggests that it may be involved in the 
process of progressive cartilage loss. These 
roles for CatK do not preclude that inhibition 
of this cysteine protease may also prevent 
subchondral bone remodeling and vascular 
invasion to cartilage, and CatK may be a dual- 
acting treatment that can affect both cartilage 
and bone catabolism.
** The Editorial Committee of Actualizaciones en Osteoleogía recognizes that the studies performed 
using the cathepsin K inhibitor odanacatib in the osteoarthritis model contribute to our understanding of 
the mechanism of action of the drug in this pathology. However, it should be noted that the company that 
developed odanacatib decided not to continue filing for FDA approval or any further development of the 
drug, due to the increased risk of stroke in post-menopausal women during the Phase 3 trial.
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Figure 4. CatK is upregulated in articular cartilage chondrocytes in the early phases of OA, and the diges-
tion of type II collagen by CatK may be associated with cartilage fibrillation. SrRan suppresses the produc-
tion of CatK significantly, especially at high doses, and may protect the cartilage from deterioration (Data 
from Ref 86).
A short-term, 28 day experiment in partially-
meniscetomized female beagles treated with a 
CatK inhibitor (GlaxoSmithKline) also suggests 
some effect of this treatment, especially on the 
medial side of the weight bearing area of the tib-
ial plateau,87 in the area of the pre-existing me-
niscus. A >75% reduction in urinary CTX-II was 
also observed within one week following menis-
cectomy and in animals treated with the inhibi-
tor, suggesting that this may prevent cleavage of 
Type II collagen and be chondroprotective. 
Head to head studies comparing another 
CatK inhibitor (Merck and Co.) to ALN in an 
ACLT model in rabbits suggest that CatK inhi-
bition at the higher dose (50 mg/kg/day, p.o., 
5x higher than the dose used to retain bone in 
OVX rats) was as effective as ALN (200 µg/kg,
3x/week, s.c., 3 times higher than the OVX 
dose) eight weeks after surgery.88 As the CatK 
inhibitor at low dose resulted in greater reten-
tion of bone volume than ALN, but was not 
as effective at preventing cartilage changes, 
the effect of CatK inhibitors may be directly on 
the cartilage matrix itself, rather than through 
suppression of subchondral bone remodeling. 
Both doses of CatK inhibitor reduced urinary 
CTX-II, although the higher dose was more 
effective, and consistent with the reduction 
in CTX-II with ALN treatment. Therefore, the 
effect of CatK inhibitor in this case is likely 
through an inhibition of type II collagen degra-
dation. 
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Conclusion
The conclusion from many of these studies 
is that anti-resorptive agents must be admin-
istered pre-emptively or in the very early stag-
es of disease to be effective. This has several 
important implications. First, it suggests that 
remodeling suppressive treatments for OA will 
be most effective in cases of post-traumatic 
injury, when the timing of the occurrence of 
injury is well known. It will probably not be a 
terribly useful therapy in age-related joint de-
generation, which develops over a long pe-
riod of time and in which the timing of events 
initiating the cartilage loss cannot be deter-
mined. Second, better and earlier detection 
methods for joint disease would be useful, 
with an emphasis on biochemical or structural 
markers for early cartilage changes.100 Imaging 
techniques that can be used to identify early 
structural changes in bone that pre-sage the 
progressive development of cartilage destruc-
tion must be developed. Recent evidence90 
suggests this may be on the near horizon. This 
study showed that progression of OA could be 
detected and predicted as long as two years 
before the appearance of radiographic OA by 
identifying synovitis (hazard ratio (HR) = 1.76-
1.81) or damage to the medial meniscus (HR 
= 1.83).  Bone marrow lesions apparent one 
year before the radiologic appearance of OA 
were an even stronger indicator (HR = 6.50). 
As BPs have been shown to have an effect on 
BMLs,24 using BMLs as an indicator to begin 
treatment with an anti-catabolic agent may 
have some merit. However, it may not be pos-
sible in the near future to predict progression 
of cartilage disease with sufficient precision or 
sufficient lead time to make the use of bone 
anti-remodeling treatments aimed to prevent 
vascular invasion feasible. Therefore, in the 
near future, we should concentrate on those 
situations in which the onset of progressive 
cartilage changes is known, and progressive 
OA changes are predictable. Thus, for now, 
these treatments may be more beneficial in 
cases of ligament tears (e.g. ACL disruption) or 
post-traumatic osteoarthritis (PTOA). However, 
it will still be necessary to determine in these 
cases whether the treatment is actually effec-
tive, and when treatment should be initiated.
Newer treatments that are incidentally anti-
catabolic on bone, such as SrRan and CatK 
inhibitors, may also have direct effects on car-
tilage that are not dependent on bone. The 
mechanism of action of these agents is impor-
tant to know and understand as well. Perform-
ing experiments that are time-sensitive in rela-
tion to the development of OA may also con-
tribute to our understanding of the mode of 
action of the various different anti-remodeling 
agents. If some or all of them are effective, are 
they effective because of their action on bone, 
because of direct effects on cartilage catabo-
lism/anabolism, or through a combination of 
these effects that may entail some feedback 
or cross talk between the bone and cartilage?
What do we need to do experimentally?
To fully evaluate the utility of bone anti-re-
modeling treatments in preventing the onset 
or progression of cartilage deterioration that 
eventually leads to OA, temporal changes in 
cartilage degradation should be evaluated us-
ing an animal model of OA exposed at differ-
ent times (and perhaps for different durations) 
to remodeling-suppressive therapies. Be-
cause the beneficial effects of such therapies 
seem to depend on preventing the early phas-
es of disease that involve vascular invasion of 
the deep layers of cartilage, an acute model 
of OA, such as the ACL transection model 
or a model of post-traumatic OA, should be 
used. Treatment with an anti-catabolic agent 
at three different time points could elucidate 
the value of the anti-remodeling therapy at dif-
ferent phases of OA progression. Treatment at 
three timepoints could be suggested: 
1) Prior to evidence of aggrecan loss or 
cartilage clefting/fibrillation.
2) Following superficial clefting and loss 
of aggrecan in the superficial layers of the ar-
ticular cartilage.
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3) Following frank subchondral sclerosis
Such a study could identify the appropri-
ate timing for treatment in these common 
human conditions that are known to lead, 
over time, to progressive cartilage deterio-
ration, and which have the advantage of a 
clear initiating time point at which treatment 
could be most effectively begun – a clini-
cally valuable outcome. And, as pointed out 
above, such a study might help to further 
expose the target tissues and mechanism of 
action of the various compounds used for 
chondroprotection – a mechanistically-valu-
able outcome.
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